Primary care providers, MD, DO, Nurse Practitioners, Physician Assistants, Nurses, Addiction Specialists, Case Managers, Pharmacists
Hepatitis C, hep C, HCV, viral hepatitis, liver disease, Simplified HCV treatment guidelines, Substance use disorder, injection drug use, Opioid epidemic, Harm reduction, Addiction medicine
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer and Director of Viral Hepatitis Programs
Philadelphia FIGHT Community Health Centers
Clinical Assistant Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Dr. Stacey B. Trooskin is Chief Medical Officer and Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and is a faculty member of the Infectious Diseases Division at the University of Pennsylvania. Dr. Trooskin received her MPH in Public Health from Yale University, her PhD (Epidemiology) from Rutgers School of Public Health and her MD from the University of Medicine and Dentistry of New Jersey, at the Robert Wood Johnson School of Medicine. Dr. Trooskin specializes in infectious diseases, HIV medicine, HIV/HCV co-infection, and internal medicine. She has an interest in public health, particularly the epidemiology of hepatitis C and identifying and overcoming barriers to testing and treatment. She recently completed a 3 year term of service as a member of the AASLD/IDSA HCV treatment guidance panel and currently serves as the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the Technical Advisory Board (TAB) of the Coalition for Global Hepatitis Elimination.
1. | Demonstrate a comprehensive understanding of the HCV care continuum | 2. | Apply Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing |
3. | Utilize AASLD/IDSA simplified HCV treatment guidelines | 4. | Provide patient education, counseling, and support across the HCV care continuum, encompassing harm-reduction principles and practices |
1. | Demonstrate a comprehensive understanding of the HCV care continuum |
2. | Apply Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing |
3. | Utilize AASLD/IDSA simplified HCV treatment guidelines |
4. | Provide patient education, counseling, and support across the HCV care continuum, encompassing harm-reduction principles and practices |
TITLE: Treating Hepatitis C in the Primary Care Setting: Establishing Clinical Readiness Through Mentored Learning
COMPONENT 2: On-demand Enduring Activity
CREDITS: 1.25 AMA PRA Category 1 Credit™ or 1.25 AANP Contact Hour (which includes 0.25 hour(s) of pharmacology)
LAUNCH DATE: November 30, 2021
EXPIRATION DATE: November 30, 2022
PRIMARY AUDIENCE: Primary care physicians, NPs, PAs, and other clinicians involved in the care of patients with or at risk of HCV infection
RELEVANT TERMS: HCV, hepatitis C, hepatitis C virus, HCV infection, hep C, primary care, PCP
COURSE FACULTY
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer
Philadelphia FIGHT
Clinical Assistant Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
LEARNING OBJECTIVES
Upon completion of this activity, the participant should be better able to:
COURSE SUMMARY
This online, interactive curriculum will provide continuing education (CME/CE) for primary care providers (PCPs) to support their competence and confidence in treating patients with chronic hepatitis C virus (HCV) infection. Small-group workshops will utilize novel collaborative-education methodologies, facilitate peer-to-peer learning, and promote sharing of strategies for overcoming challenges inherent to adoption of new clinical practices.
PLANNING COMMITTEE
Michelle Frisch, MPH, CHCP
Vice President, Operations
National Association for Continuing Education
Plantation, FL
Angela Golden, DNP, FNP-C, FAANP
NP Obesity Treatment Clinic
NP from Home, LLC
Assistant Professor (Ret), Northern Arizona University
Past President, American Association of Nurse Practitioners
Munds Park, AZ
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL
Jeanette Ruby, MD
Vice President, Scientific Services
Integritas Communications Group
Hoboken, NJ
Jim Kappler, PhD
Integritas Communications Group
Hoboken, NJ
Becky Carney, MSPT
Senior VP, Educational Strategy
Integritas Communications Group
Hoboken, NJ
Christa Master
Vice President, Account Services
Integritas Communications Group
Hoboken, NJ
ACCREDITATION INFORMATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and Integritas Communications. NACE is accredited by the ACCME to provide continuing medical education for physicians.
NACE designates this enduring activity for 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and Integritas Communications. The NACE is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 1.25 contact hours (which includes 0.25 hour(s) of pharmacology).
DISCLOSURE POLICY
Accredited education provided by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE accredited education are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest will be mitigated prior to the activity.
NACE defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
INDIVIDUAL DISCLOSURES
Course Faculty
Stacey B. Trooskin, MD, PhD, MPH: Advisory Board Member: Gilead Sciences Contracted Research: Gilead Sciences
Dr. Trooskin’s relevant financial relationships have been mitigated.
Planning Committee
Michelle Frisch, MPH, CHCP: No financial relationships to disclose
Angela Golden, DNP, FNP-C, FAANP: No financial relationships to disclose
Gregg Sherman, MD: No financial relationships to disclose
Jeanette Ruby, MD: No financial relationships to disclose
Jim Kappler, PhD: No financial relationships to disclose
Becky Carney, MSPT: No financial relationships to disclose
Christa Master: No financial relationships to disclose
STATEMENT OF COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
COURSE VIEWING REQUIREMENTS
Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
Additional Recommendations and Requirements | |
Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
Audio | - Microphone - Speakers or headphones - Audio recording support |
Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |